GENB
Generate Biomedicines, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Generate Biomedicines, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Generate Biomedicines, Inc.
14.49
Linked news
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Flagship PioneeringFlagship Pioneering | $1.1B | 62.64% | 0.00% | |
| 2 | FMRFMR | $88.1M | 5.22% | +23.81% | |
| 3 | Capital World InvestorsCapital World Investors | $71.1M | 4.21% | +5.28% | |
| 4 | BraidwellBraidwell | $55.4M | 3.28% | −8.60% | |
| 5 | T. Rowe Price AssociatesT. Rowe Price | $36.4M | 2.16% | +2.23% | |
| 6 | Norges BankNorges Bankindex-like | $35.3M | 2.09% | — | |
| 7 | Arch VentureArch Venture | $32.8M | 1.94% | 0.00% | |
| 8 | Harbourvest PartnersHarbourvest Partners | $29.1M | 1.72% | 0.00% | |
| 9 | BlackRockBlackRockindex-like | $28.0M | 1.66% | new | |
| 10 | Baker Bros. AdvisorsBaker Bros. | $24.0M | 1.42% | 0.00% | |
| 11 | JPMorgan ChaseJPMorgan Chase | $23.8M | 1.41% | −52.17% | |
| 12 | Deep Track CapitalDeep Track Capital | $22.5M | 1.33% | new | |
| 13 | ARK Investment ManagementARK | $21.7M | 1.28% | +157.74% | |
| 14 | Vanguard Capital ManagementVanguardindex-like | $19.1M | 1.13% | +762.59% | |
| 15 | Harvard ManagementHarvard | $18.7M | 1.11% | 0.00% | |
| 16 | NvidiaNvidia | $14.1M | 0.83% | 0.00% | |
| 17 | Davern Capital PartnersDavern Capital Partners | $13.9M | 0.82% | +39.35% | |
| 18 | SirenSiren | $12.4M | 0.74% | 0.00% | |
| 19 | Geode Capital ManagementGeodeindex-like | $12.4M | 0.73% | +521.60% | |
| 20 | State StreetState Streetindex-like | $8.9M | 0.53% | new | |
| 21 | Affinity Asset AdvisorsAffinity Asset | $6.7M | 0.40% | +14.29% | |
| 22 | Morgan StanleyMorgan Stanley | $6.4M | 0.38% | +12.06% | |
| 23 | UBS GroupUBS | $5.5M | 0.33% | −8.53% | |
| 24 | Sphera Funds ManagementSphera Funds | $4.1M | 0.24% | +32.43% | |
| 25 | Charles Schwab Investment ManagementCharles Schwabindex-like | $3.8M | 0.22% | new |
86 managers report $1.7B of Generate Biomedicines on form 13F for the quarter ended Jun 30 '26. 7 of them hold 80% of it; Flagship Pioneering is largest at 62.64%.
No implied move.
No implied move.
Expected move
No implied move.